Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 122

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 122
---
 a wholly owned subsidiary of the Company.

In consideration for the contribution of all of their shareholdings in Predecessor to the Company, the Company issued to the former Predecessor shareholders an aggregate of 23,171,642 restricted shares of the Company’s common stock, representing 40% of the outstanding shares of the Company immediately following the closing. As of September 30, 2024, due to technical reasons, the shares haven’t been issued by the transfer agent yet. During the fourth quarter of 2024 these shares were issued.

The company has calculated Fair value of the Consideration shares based on the acquired fair value using the price of transactions close to the acquisition date. The Company didn’t use quoted market prices of Revium RX due to the negligible volume of trading in its shares with no records of trading close to the transaction date.

Revium RX is a public company listed on the over the counter market in the U.S. and due to the negligible volume of trading in its shares management does not believe it is an appropriate basis to determine the value of the consideration shares based on the stock exchange quoted price. The Predecessor is a private company with no quoted price available for its shares. The transaction occurred between a willing buyer and a willing seller and the merger ratio reflects the relative fair values of both of the companies (the buyer) and the acquired company. Management has determined to evaluate the fair value of the consideration based on the fair value of Predecessor from a private placement transaction.

<div align='center'>F-15</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 4 – ACQUISITION (Cont.)

The Company allocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on their fair values, which were determined using generally accepted valuation techniques based on estimates and assumptions made by management. This is an initial evaluation, and final assessment will be made within one year.

The initial allocation of the purchase price and the fair values of the assets acquired, and liabilities assumed in the Acquisition are as follows:

| Consideration                                               |     |        |   |
| Total Consideration                                         |     | 14,307 |   |
| Less: Cash acquired                                         |     |   (729 | ) |
| Total consideration, net of cash acquired                   |     | 13,578 |   |
|                                                             |